RAPT Therapeutics’ (RAPT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for RAPT Therapeutics’ Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.76) EPS and FY2026 earnings at ($0.91) EPS.

Several other equities research analysts also recently issued reports on the company. Wells Fargo & Company lowered their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.29.

RAPT Therapeutics Price Performance

RAPT Therapeutics stock opened at $1.25 on Monday. The company has a market capitalization of $43.70 million, a price-to-earnings ratio of -0.45 and a beta of -0.31. RAPT Therapeutics has a one year low of $0.79 and a one year high of $9.65. The company’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.53.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). As a group, sell-side analysts anticipate that RAPT Therapeutics will post -2.14 earnings per share for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Trustees of Columbia University in the City of New York bought a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $116,000. Shay Capital LLC bought a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $81,000. RTW Investments LP bought a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $18,587,000. Redmile Group LLC lifted its stake in shares of RAPT Therapeutics by 1,183.4% in the fourth quarter. Redmile Group LLC now owns 6,475,317 shares of the company’s stock valued at $10,231,000 after buying an additional 5,970,785 shares during the period. Finally, Nuveen Asset Management LLC lifted its stake in RAPT Therapeutics by 50.5% during the fourth quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company’s stock worth $185,000 after purchasing an additional 39,216 shares during the period. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.